Contracts & Grants

Information is courtesy of the Office of Sponsored Projects. Each listing includes the faculty member’s name and school(s) appointments at The University of Texas Health Science Center at Houston, project title, contracting or granting agency, and funding amount.

New

Jeffrey K. Actor, Medical School (MS), Cytogenix Inc., $15,885, Immunomodulation of Sepsis.

Ben J. Barnett, MS, Gilead Sciences, $37,940, A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment- Experienced, HIV-1 Infected Subjects Comparing Ritonavir Boosted GS-9137 (GS-9137/R) Versus a Comparator Ritonavir Boosted Protease Inhibitor (CPI/R) in Combination with a Background Antiretroviral Therapy; and Tibotec Pharmaceuticals, $41,934, A Phase III Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Including TMC114/RTV and an Investigator-Selected OBR in HIV-1 Infected Subjects with Limited to No Treatment.

Cristina S. Barroso, School of Public Health (SPH), Robert Wood Johnson Foundation, $49,985, The Impact of Texas Senate Bill 42 on Middle School Children’s Level of Physical Activity.

Staley A. Brod, MS, Abbott Laboratories, $432,515, A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety Tolerability, and Efficacy Study of the Human Anti-Il-12 Antibody ABT-874 in Subjects with Multiple Sclerosis with a 24-Week Double-Blind, Active Extension Phase.

John Y. Choi, MS, Yale University, $48,908, Insulin Resistance Intervention in Stroke.

Dennis J. Ciancio, MS, U.S. Department of Education, $1,105,785, Reading and Writing Education Research Grants Program.

Ali E. Denktas, MS, Osiris Therapeutics Inc., $175,165, Safety of Provacel in Subjects Following Acute Mycardial Infarction.

Maria E. Fernandez, SPH, Baylor College of Medicine, $125,514, Redes En Accion: National Latino Cancer Research Network.

James C. Grotta, MS, Novo Nordisk Pharmaceuticals Inc., $35,268, Randomized, Double-Blind, Placebo Controlled, Multi- Center, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (Novoseven / Niastase) in Acute Intracerebral Haemorrhage.

Sandra K. Hanneman, School of Nursing, Society of Critical Care Medicine, $15,000, Multisite Randomized Clinical Trial of Horizontal Positioning to Prevent and Treat Pulmonary Complications in Mechanically Ventilated Critically Ill Patients: A Pilot Study.

Adelaide A. Hebert, MS, Sinclair Pharmaceuticals Limited, $86,385, A Multicenter, Randomized, Vehicle-Controlled Clinical Study to Examine the Efficacy and Safety of Atopiclair in the Management of Mild to Moderate Atopic Dermatitis in Infants and Children.

Vasanthi Jayaraman, MS and Graduate School of Biomedical Sciences (GSBS), Baylor College of Medicine, $22,012, Structure- Function Investigations of Glutamate Receptors Using Spectroscopy and Electrophysiology.

Arthur H. Jeske, Dental Branch (DB), Novalar Pharmceuticals, $62,660, A Phase 3, Multicenter, Randomized Blinded Control Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Dental Patients Undergoing Mandibular Procedures (Nova 04- 100); and Novalar Pharmceuticals, $62,660, A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Dental Patients Undergoing Maxillary Procedures (Nova 04-200).

Lillian S. Kao, MS, Wyeth-Ayerst Research Inc., $91,357, A Multicenter, Open Label, Randomized Comparative Study of Tigecycline vs. Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Patients with Complicated Intra- Abodominal Infection.

Bruce C. Kone, MS and GSBS, Harris County Hospital District, $58,464, Ryan White Title I (Position of Associate Medical Director).

Renhao Li, MS and GSBS, National Institutes of Health (NIH), National Heart, Lung and Blood Institute, $1,245,265, Structure and Function of Platelet Glycocprotein LB-IX-V Complex.

John Mohr, MS, Bristol-Myers Squibb Co., $34,568, Risk Factors with Dysglycemias in Patients Receiving Gatifloxacin and Levofloxacin; and Elan Pharmaceuticals, $67,929, Evaluation of the Accuracy of Multiple In-Vitro Susceptibility Testing Systems Against Bloodstream Isolates of P. Aeruginosa.

Maria T. Morandi, SPH, Mickey Leland National Urban Air Toxics Research Center, $24,872, Performance Evaluation of the 3M Charcoal Vapor Monitor for Monitoring Low Ambient Concentrations of VOCS: A Critical Review of the Literature.

Joe C. Ontiveros, DB, Discus Dental Inc., $3,500, Flexural and Retentive Strength of Provisional Cements.

Luis Ostrosky-Zeichner, MS, Merck & Co. Inc., $64,518, A Retrospective Review of the Incidence and Magnitude of Actual and Potential Drug Interactions with Current Antifungals Among Hospitalized Patients with Candidemia.

Ronald Portman, MS, Astrazeneca, $77,301, A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A Four-Week, Multicenter, Randomized, Double-Blind Study with a One-Year Open-Label, Follow-Up Period.

John D. Reveille, MS and GSBS, Centocor Inc., $514,006, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, a Fully Human Anti-TNFA Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondylitis; and UT M. D. Anderson Cancer Center, $50,412, Polymorphic Human Leukocyte Antigen.

Mya C. Schiess, MS, Teva Pharmaceutical Industries Ltd., $185,016, TVP-1012/500: A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study of Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects.

Beatrice J. Selwyn, SPH, Baylor College of Medicine, $41,496, Houston Initiative for Global Health Education and Research (Higher).

William D. Spears, SPH, Bexar County Community Health Collaborative, $175,002, 2006 Bexar County Community Health Assessement.

Charles T. Van Buren, MS, Novartis Pharmaceuticals Corp., $130,468, A 24-Month, Multi-Center, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration-Controlled Certican in Two Doses (1.5 and 3.0 Mg/Day Starting Doses) with Reduced Neoral Versus 1.44 Mg Myfortic with Standard Dose Neoral.

Nadarajah Vigneswaran, DB, NIH, National Institute of Dental and Craniofacial Research, $148,500, Role of Cystatins in Oral Cancer Metastasis.

Ouida L.Westney, MS, United Biosource Corporation, $81,890, A Multicenter, Multiphase, Single Arm, Open Label Study to Evaluate the Effects of Tolterodine ER in Conjunction with Behavioral Intervention on Subject Satisfaction and Overactive Bladder Symptoms [Urgency Urinary Incontinence (UUI), Urgency, Frequency].

Rick A.Wetsel, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases and GSBS, NIH, National Institute of Allergy and Infectious Diseases, $74,250, Mouse C4B-Binding Protein in Adaptive Immunity.

Renewal

Peter J. Christie, MS and GSBS, NIH, National Institute of General Medical Sciences, $1,594,492, Translocation of DNA Across the Agrobacterium Envelope.

John O’Brien, MS and GSBS, NIH, National Eye Institute, $1,023,431, Regulation of Retinal Gap Junctions.

John D. Reveille, MS and GSBS, Oregon Health Sciences University, $116,411, Analysis of Genetic Susceptibility to Anterior Uveitis.